Literature DB >> 9563901

Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment.

S Fan1, B Cherney, W Reinhold, K Rucker, P M O'Connor.   

Abstract

In the present study, we report our findings on the impact of p53 disruption on the sensitivity of human cell lines to the antimitotic agents Taxol and vincristine. Comparisons of cell survival and apoptosis were made with y-irradiation and, in some cases, several other DNA-damaging chemotherapeutic agents. Studies in eight Burkitt's lymphoma and lymphoblastoid cell lines (four wild-type p53 and four mutant p53 cell lines) revealed that the DNA-damaging agents assayed tended to exhibit less growth inhibition in the mutant p53 cell lines compared to the wild-type p53 cell lines. In contrast, no significant correlation was apparent between p53 gene status and the growth-inhibitory potency of Taxol or vincristine in these eight cell lines. We also found that contrary to gamma-irradiation, Taxol and vincristine could induce apoptosis in lymphoma cell lines harboring p53 mutations. These observations were explored further in lymphoblastoid VDSO cells (wild-type p53) from a normal individual and stably transfected VDSO derivatives lacking p53 function due to expression of the human papillomavirus type-16 E6 gene. We found that p53 disruption in VDSO/E6 cells blocked y-ray-induced apoptosis and afforded a survival advantage to VDSO/E6 cells compared to control-transfected cells. In contrast, p53 disruption did not affect Taxol- or vincristine-induced apoptosis or survival in VDSO cells. The effect of p53 disruption on Taxol sensitivity was explored further in the breast carcinoma MCF-7 and colon carcinoma HCT-116 cell lines that had been stably transfected with either the human papillomavirus type-16 E6 gene or a dominant-negative mutant p53 gene. Again, in these cell model systems, we found that p53 disruption did not affect the growth-inhibitory potency of Taxol. Taken together, our results suggest that p53 status is not a dominant factor in the mechanism by which antimitotic agents induce apoptosis and reduce survival in immortalized human cell lines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9563901

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

1.  TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Authors:  Hervé Bonnefoi; Martine Piccart; Jan Bogaerts; Louis Mauriac; Pierre Fumoleau; Etienne Brain; Thierry Petit; Philippe Rouanet; Jacek Jassem; Emmanuel Blot; Khalil Zaman; Tanja Cufer; Alain Lortholary; Elisabet Lidbrink; Sylvie André; Saskia Litière; Lissandra Dal Lago; Véronique Becette; David A Cameron; Jonas Bergh; Richard Iggo
Journal:  Lancet Oncol       Date:  2011-05-11       Impact factor: 41.316

Review 2.  Microtubule-binding agents: a dynamic field of cancer therapeutics.

Authors:  Charles Dumontet; Mary Ann Jordan
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

3.  Vincristine and lomustine induce apoptosis and p21(WAF1) up-regulation in medulloblastoma and normal human epithelial and fibroblast cells.

Authors:  Zakia Shinwari; Pulicat S Manogaran; Salman A Alrokayan; Khaled A Al-Hussein; Abdelilah Aboussekhra
Journal:  J Neurooncol       Date:  2007-12-06       Impact factor: 4.130

4.  Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.

Authors:  Sebastian Winsel; Anette Sommer; Julia Eschenbrenner; Kevin Mittelstaedt; Ulrich Klar; Stefanie Hammer; Jens Hoffmann
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

5.  Syzygium cumini inhibits growth and induces apoptosis in cervical cancer cell lines: a primary study.

Authors:  D Barh; G Viswanathan
Journal:  Ecancermedicalscience       Date:  2008-08-21

Review 6.  Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas.

Authors:  L Loni; M Del Tacca; R Danesi
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

7.  p53 as a potential predictive factor of response to chemotherapy: feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients.

Authors:  H Bonnefoi; A Ducraux; S Movarekhi; M F Pelte; S Bongard; E Lurati; R Iggo
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

Review 8.  Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group.

Authors:  Emiel J T Rutgers; Philip Meijnen; Hervé Bonnefoi
Journal:  Breast Cancer Res       Date:  2004-06-16       Impact factor: 6.466

9.  Styrylpyrone Derivative (SPD) induces apoptosis in a caspase-7-dependent manner in the human breast cancer cell line MCF-7.

Authors:  Alvin Teck Chien Lee; Hawariah Lope Pihie Azimahtol; Ann Na Tan
Journal:  Cancer Cell Int       Date:  2003-10-04       Impact factor: 5.722

10.  Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series.

Authors:  Athina Stravodimou; Khalil Zaman; Ioannis A Voutsadakis
Journal:  ISRN Oncol       Date:  2014-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.